Showing 2011-2020 of 2898 results for "".
- SoftWave Tissue Regeneration Technologies Announces Plan for Cellulite Trialhttps://modernaesthetics.com/news/softwave-tissue-regeneration-technologies-announces-plan-for-cellulite-trial/2472974/SoftWave Tissue Regeneration Technologies plans to start a 60-patient study to evaluate the safety and efficacy of the DermaGold device for the temporary improvement in the appearance of cellulite. The company has a patent for the use
- Online Consults On the Rise; Credentials Matterhttps://modernaesthetics.com/news/online-consults-on-the-rise-credentials-matter/2472967/The British Association of Aesthetic Plastic Surgeons (BAAPS) is reporting a “massive upswing” in demand for virtual consultations during lockdown, but urges the public to remain cautious. Despite predicted financial strains being felt acro
- New from Cutera: Get to Know Fraxis PROhttps://modernaesthetics.com/news/new-from-cutera-get-to-know-fraxis-pro/2472965/Cutera, Inc. is launching Fraxis PRO progressive dermal remodeling technology. Fraxis PRO combines fractional CO2 for skin resurfacing and radiofrequency microneedling for dermal remodeling in a single device. Fraxis PRO treats: Fine Lines Wr
- Revance’s DaxibotulinumtoxinA for Injection Looks Good in Phase 2 Studies of Forehead Lines and Crow’s Feethttps://modernaesthetics.com/news/revances-daxibotulinumtoxina-for-injection-looks-good-in-phase-2-studies-of-forehead-lines-and-crows-feet/2472963/Revance Therapeutics, Inc.’s next-generation neuromodulator product, DaxibotulinumtoxinA, safely and effectively smoothed forehead lines and Crow’s feet with a median duration of 27 weeks in forehead lines and 24 weeks in crow’s feet achieved in at least one treatment group
- Endo’s Qwo Scores FDA Nod for Cellulite Treatmenthttps://modernaesthetics.com/news/endos-qwo-scores-fda-nod-for-cellulite-treatment/2472961/The FDA has given its nod to an entirely new way to address cellulite. Endo Aesthetic’s Qwo (collagenase clostridium histolyticum-aaes) is the first injectable treatment for moderate to severe cellulite of the buttocks in adult women. When fat in cellulite-prone areas swells and e
- CE Mark Plus Launch for System ONE-M from TOOsonix A/Shttps://modernaesthetics.com/news/ce-mark-plus-launch-for-system-one-m-from-toosonix-as/2472959/TOOsonix A/S is launching its CE-marked System ONE-M for color-independent tattoo removal, solar lentigines, spider veins, angiomas, telangiectasia and other aesthetic conditions. System ONE-M is a focused ultr
- New Survey on Reopening after COVID-19: If You Wear Masks, They Will Come Backhttps://modernaesthetics.com/news/new-survey-on-reopening-after-covid-19-if-you-wear-masks-they-will-come-back/2472957/Fully 85 percent of people plan to return to aesthetic treatments within 12 months of COVID-19 restrictions being lifted, and 63 percent plan to return to practices within just three months of restrictions being lifted in their respective countries, according to a
- DocClocker App Now Features Remote Check-In to Prevent Spread of COVID-19 in Medical Practiceshttps://modernaesthetics.com/news/docclocker-app-now-features-remote-check-in-to-prevent-spread-of-covid-19-in-medical-practices/2472956/DocClocker, an app that allows patients to receive real-time wait time reporting of their medical providers, enabling patients to avoid long waits in medical waiting rooms and limit COVID-19 exposure risks, now offers DocClocker Remote Check-In. As practices reopen amid the COVID-19 pan
- Candela’s CO2RE Laser Platform Scores Health Canada Approval for Two New Gynecological Indicationshttps://modernaesthetics.com/news/candelas-co2re-laser-platform-scores-health-canada-approval-for-two-new-gynecological-indications/2472955/Health Canada has approved Candela’s CO2RE laser for the treatment of genitourinary syndrome of menopause (GSM) and stress urinary incontinence (SUI) in adult women. The CO2RE laser, a sing
- FDA Approves Juvéderm Voluma XC for Augmentation for Chin Regionhttps://modernaesthetics.com/news/fda-approves-juvederm-voluma-xc-for-augmentation-for-chin-region/2472953/The FDA has approved Allergan Aesthetics' Juvéderm Voluma XC for the augmentation of the chin region to improve the chin profile in adults over the age of 21. According to Allergan Aesthetics, an AbbVie company, the Juvéderm Collection of Fillers has the broadest portfolio of sp